]> 2026-04-12T04:07:26-07:00 Curcumin 0 en Curcumin, the active ingredient in turmeric, is generally well-tolerated with minimal side effects. As a dietary supplement, it has the lowest toxicity rating. This number (1) represents minimal toxicity. Remember, however, that while curcumin is showing some promising results in laboratory studies, it is not an FDA-approved cancer treatment and is currently under investigation. 2025-01-18T08:19:56Z 2460693.8471759 Curcumin 0 [2,"smw-datavalue-wikipage-property-invalid-title","Has original text","Curcumin\n\nThis is an ingredient in the Indian cooking spice, turmeric. It has been shown to inhibit\nthe growth of cancer cells of various types in laboratory studies via numerous different\nmechanisms (272). Like genistein, it inhibits the tyrosine kinase signaling and also\ninhibits angiogenesis. Perhaps most importantly, it inhibits proteins that prevent\ndamaged cells from undergoing apoptosis, a family of genes known as nuclear factor\nkappa B. Of all of the supplements on this list it is the most potent anti-cancer agent in\nlaboratory studies. However, it also should be noted that its bioavailability from oral\nintake is limited, although bioavailability supposedly is increased when curcumin is\ncombined with piperine (the main ingredient in black pepper). The Life Extension\nFoundation sells a version of curcumin that they claim has much greater bioavailability\nthan anything else on the market. Despite the limited bioavailability, there is some\nevidence of clinical effectiveness. In a study of dermatitis induced by radiotherapy for\nbreast cancer, a double-blind placebo controlled trial compared a placebo with curcumin\n(2 grams three times\/day), both of which were taken throughout radiation treatment.\nSignificantly less dermatitis occurred in patients receiving curcumin (273).\n\nCurcumin has also been used in combination with a second supplement, quercetin, (see\nbelow) for the treatment of an inherited disorder of the colon in which hundreds of\nadenomas develop and eventually colon cancer (274). Five patients with the disorder\nreceived 480 mg of curcumin and 20 mg of Quercetin three times daily. Polyp number\nand size were assessed at baseline and then six months after starting the supplements.\nFor all patients there was a decrease in polyp size and number, which was statistically\nsignificant."] Curcumin# ERRa3f62c6665776505f0db7c26c19aebf1 0 [2,"smw-datavalue-wikipage-property-invalid-title","Has clinical trial explanation","Curcumin is being studied in preclinical and early clinical trials to assess its potential as an anti-cancer agent. While not directly focusing on survival metrics like OS or PFS, these studies explore its biochemical mechanisms that could influence cancer cell behavior and patient symptoms."] Curcumin# ERR3019b4979f53631ee3912d6416218f93 0 [2,"smw-datavalue-wikipage-property-invalid-title","Has Usefulness Explanation","Curcumin has demonstrated potential in laboratory studies for its anti-cancer properties including inhibition of key signaling pathways, promotion of cancer cell apoptosis, and reduction of inflammation and angiogenesis. Its clinical utility in cancer care, particularly in glioblastoma, remains under investigation with early evidence suggesting benefits in symptom management and possibly enhancing the effects of conventional treatments."] Curcumin# ERR0de0b09fdf871942cb9b8a10a8978dce Has treatment name 102 en Has treatment name